Shepherd Center Radio

Researchers are reporting exciting work under way to develop new treatments for multiple sclerosis. A number of clinical trials are under way at Shepherd Center and elsewhere.The U.S. Food and Drug Administration (FDA) has approved Plegridy™ (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis (RMS). Clinical trials show the drug reduces relapses, disability progression and brain lesions.MS management can be divided into three areas: relapse treatment, symptom management and disease modification.Listen in as Ben Thrower, M.D., discusses the latest developments in MS management at Shepherd Center.